Twist Bioscience Narrows FY2025 Sales Guidance from $372.000M-$379.000M to $374.000M-$376.000M vs $376.206M Est

Author: Benzinga Newsdesk | August 04, 2025 06:20am

Total revenue to be in the range of $374 million to $376 million, revised from previous guidance of $372 million to $379 million, indicating growth of 19 to 20 percent year over year, including:

• SynBio revenue of $144 million to $145 million, growth of 16 to 17 percent
• NGS revenue of $207 million to $208 million, growth of 22 to 23 percent
• Biopharma revenue of $23 million, growth of 13 percent 

Gross margin is projected to be approximately 50.5% to 51.0% for fiscal 2025 with quarterly sequential improvements, compared to previous guidance of 49.5%.

Adjusted EBITDA of approximately $(45.0) million to $(47.0) million for fiscal 2025, compared to previous guidance of $(48.0) million to $(53.0) million

Posted In: TWST